FDA Expands Indication for Boehringer’s Hernexeos (Zongertinib) to Include First-Line HER2-Mutant NSCLC

On February 26, the FDA issued an accelerated secondary approval for Boehringer Ingelheim’s Hernexeos (zongertinib), specifically for adult patients diagnosed with advanced NSCLC.¹ This regulatory milestone targets malignancies characterized by HER2 tyrosine kinase domain activating mutations, which must be identified using an FDA-authorized diagnostic tool.

This decision represents a significant therapeutic expansion for the drug, which first secured accelerated approval in August 2025 for patients who had previously received systemic treatment.¹ The review was conducted under the Commissioner’s National Priority Voucher (CNPV) pilot program, a strategic regulatory initiative created to expedite the approval of treatments that address urgent national health priorities.

The application for Hernexeos was submitted January 13, 2026, and a final decision was reached in just 44 days.² Under the CNPV, the FDA aims to reduce traditional 10–12-month review windows to as little as one to two months for qualifying sponsors.

“As a part of the national priority voucher program, the FDA is on the hunt for game-changing therapies that can qualify for a priority review. In this case a final decision was rendered 44 days after the filing date,” said FDA Commissioner Marty Makary, MD, MPH.¹ “Patients and sponsors deserve an efficient FDA process that cuts out idle time and delivers powerful treatments safely and quickly for the American people.”

To qualify for the CNPV, manufacturers must meet specific criteria, including a commitment to domesticating manufacturing as a matter of national security, increasing drug affordability, or addressing significant unmet public health needs.

“National priority vouchers are granted to a select group of products where the company has agreed to increase affordability, domesticate manufacturing as a national security issue, or address an unmet public health need,” Makary said in a release.³ “We are pioneering new ways of bringing these cures and meaningful treatments to the market faster.”

The FDA's decision was supported by efficacy data from a treatment-naïve cohort in the Phase Ib Beamion LUNG-1 trial.¹ In this study of 72 patients, Hernexeos demonstrated a 76% objective response rate.² Furthermore, 64% of patients maintained a duration of response for at least six months.¹ This clinical performance marks a notable departure from the current standard of care, where expected response rates typically range between 30% and 45%.²

“Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy, a manageable safety profile, and once daily oral administration,” said Dr. John Heymach, coordinating investigator for the Beamion Lung-1 trial and chair of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center.⁴ “Now these patients finally have a targeted treatment option that they can receive immediately following identification of a HER2 mutation.”

How Does Hernexeos Function?

Hernexeos functions as an irreversible, HER2-selective tyrosine kinase inhibitor. The molecule was engineered to specifically inhibit HER2 while sparing wild-type EGFR, a design intended to manage toxicity.¹ In a pooled safety population, the most common adverse reactions included diarrhea (54%), rash (28%), hepatotoxicity (27%), and fatigue (25%). Dose discontinuations due to adverse events occurred in 6% of patients.⁴

For the pharmaceutical industry, the CNPV program utilizes a multidisciplinary “tumor board-style” review model to facilitate these rapid turnarounds.⁵ “Using a common-sense approach, the national priority review program will allow companies to submit the lion's share of the drug application before a clinical trial is complete so that we can reduce inefficiencies,” Makary said in a June press release. “The ultimate goal is to bring more cures and meaningful treatments to the American public,” he said.

Boehringer Ingelheim is continuing to investigate the therapy in broader clinical settings, including the Phase III Beamion LUNG-2 study for first-line treatment.¹ Continued approval for this indication may depend upon the verification of clinical benefit in confirmatory trials.

References

1. Jacobus N. FDA approves Hernexeos under National Priority Voucher Program. Pharmaceutical Executive. Published February 27, 2026. Accessed March 2, 2026. https://www.pharmexec.com/view/fda-approves-hernexeos-national-priority-voucher-program 

2. U.S. Food and Drug Administration. FDA grants second approval under the National Priority Voucher pilot program. U.S. Food and Drug Administration. Published February 26, 2026. Accessed March 2, 2026. https://www.fda.gov/news-events/press-announcements/fda-grants-second-approval-under-national-priority-voucher-pilot-program

3. U.S. Food and Drug Administration. FDA awards second batch of national priority vouchers. U.S. Food and Drug Administration. Published November 6, 2025. Accessed March 2, 2026. https://www.fda.gov/news-events/press-announcements/fda-awards-second-batch-national-priority-voucher-program

4. Boehringer Ingelheim. FDA approves Hernexeos, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option. Boehringer Ingelheim. Published February 26, 2026. Accessed March 2, 2026. https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/fda-approves-hernexeos-first-line-lung-cancer

5. James D. FDA continues to expand National Priority Voucher Program. Pharmaceutical Executive. Published November 7, 2025. Accessed March 2, 2026. https://www.pharmexec.com/view/fda-expand-national-priority-voucher-program